JAGSNPHARM Intraday Analysis...

JAGSNPHARM Share Price

Open 35.00 Change Price %
High 35.50 1 Day -0.75 -2.10
Low 34.55 1 Week -2.80 -7.43
Close 34.90 1 Month -5.50 -13.61
Volume 17278 1 Year -6.25 -15.19
52 Week High 50.85
52 Week Low 25.80
JAGSNPHARM Important Levels
Resistance 2 35.78
Resistance 1 35.42
Pivot 34.98
Support 1 34.38
Support 2 34.02
NSE INDIA Most Active Stocks
JPASSOCIAT 20.05 -4.52%
GMRINFRA 19.30 0.26%
UNITECH 5.90 9.26%
RCOM 20.85 -3.92%
SUZLON 17.65 -2.49%
JPINFRATEC 16.60 11.41%
JPPOWER 5.25 -2.78%
3IINFOTECH 4.55 12.35%
IBREALEST 205.50 -0.32%
SBIN 276.40 -1.16%
More..
NSE INDIA Top Gainers Stocks
AUSTRAL 0.20 33.33%
FCSSOFT 0.25 25.00%
MAHASTEEL 71.70 19.30%
WSI 10.20 18.60%
GINNIFILA 62.40 15.02%
BEPL 58.80 14.51%
NAKODA 0.40 14.29%
SHAKTIPUMP 471.75 12.63%
3IINFOTECH 4.55 12.35%
KSBPUMPS 770.45 12.13%
More..
NSE INDIA Top Losers Stocks
VISESHINFO 0.10 -33.33%
LCCINFOTEC 0.20 -20.00%
NICCO 0.35 -12.50%
SPCENET 0.40 -11.11%
SERVALL 2.80 -11.11%
MVL 0.45 -10.00%
MVL 0.45 -10.00%
KARMAENG 49.70 -9.96%
BLUEBLENDS 55.95 -9.25%
SMPL 1.55 -8.82%
More..

Jagsonpal Pharmaceuticals Limited (NSE: JAGSNPHARM)

JAGSNPHARM Technical Analysis 4
As on 28th Jun 2017 JAGSNPHARM Share Price closed @ 34.90 and we RECOMMEND Sell for LONG-TERM with Stoploss of 38.32 & Strong Sell for SHORT-TERM with Stoploss of 41.29 we also expect STOCK to react on Following IMPORTANT LEVELS.
JAGSNPHARM Target for June
1st Target up-side 43.72
2nd Target up-side 47.69
3rd Target up-side 51.66
1st Target down-side 32.38
2nd Target down-side 28.41
3rd Target down-side 24.44
Jagsonpal Pharmaceuticals Limited ( NSE INDIA Symbol : JAGSNPHARM )
Sector : Pharmaceuticals - Formulations And Other Stocks in Same Sector
JAGSNPHARM
34.90 -0.75 (-2.10 %)
LT : Sell
ST : Strong Sell
AMRUTANJAN
678.35 -5.40 (-0.79 %)
LT : Buy
ST : Sell
JAGSNPHARM Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 32.66 Sideways
MFI (14) MFI is 60.74 Sideways
CCI (20) CCI is Below -100 Over Sold
WILLIAM %R (14) William %R is Below -80 Over Sold
ADX (14) ADX is 14.44 Range Bound
PSAR Stoploss For Short Sell 39.41
10 Day Avg Volume Traded 52.50 % More then 10 Day Average Volume
JAGSNPHARM Other Details
Segment EQ
Market Capital 0.00
Sector Pharmaceuticals - Formulations
Industry
Offical website
JAGSNPHARM Address
JAGSNPHARM
N/A
Interactive Technical Analysis Chart Jagsonpal Pharmaceuticals Limited ( JAGSNPHARM NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Jagsonpal Pharmaceuticals Limited
JAGSNPHARM Business Profile
Jagson Pharma is in the Pharmaceuticals - Formulations sector. Jagsonpal Pharmaceuticals (JAGSONPH) is a pharmaceutical company producing drugs and formulations. The company was incorporated in 1978 as a private limited company and went public in 1986. The company specializes in developing and manufacturing bulk drugs and pharmaceutical formulations. It focuses on several therapeutic groups like anti-arthritics, anti-inflammatories, analgesics, anti-spasmodics, progesterones, anabolic steroids, anesthetics and anti-fungals. Top selling brands include Lycored, Maintane, Metadec, Metabol, Doxypal DR, Parvon, and Indocap SR. The company manufactures active pharmaceutical ingredients (APIs) like Allylestrenol, Disulfiram, Tolnaftate, ..etc. The bulk drug range includes dextropropoxyphene HCl, tolnaftate, dextropropoxyphene napsylate and thiopental sodium. The manufacturing facility in Delhi is WHO and GMP-certified for the production of various dosage forms and bulk drugs and intermediates. The company also maintains a number of dedicated contract manufacturing facilities around the globe. It has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe. The distribution network in India is comprised of over 1,500 authorized stockists who are serviced by depots. The products are retailed at over 125,000 pharmacies. The company is represented by 2,500 agents worldwide and has offices in three continents. The company`s operations span Russia, USA, Brazil, Ukraine, Sri Lanka, Cameroon, Argentina, Thailand, Germany, Switzerland, Korea, Egypt and Vietnam. The company has a sales office in New York through which it services North and Latin American clients and in Belarus, it has an operation center with a sales and distribution team. The current market capitalisation stands at Rs 23.71 crore.The company has reported a standalone sales of Rs 36.79 crore and a Net Profit of Rs 0.01 crore for the quarter ended Sep 2013. The company management includes R P S Kochhar - Chairman & Managing Director, S K Goyal - Director, Govind Deo - Additional Director, Bharat Sinh - Additional Director, Ishpal Singh Ghai - Additional Director. It is listed on the BSE with a BSE Code of 507789 and the NSE with an NSE Code of JAGSNPHARM. Its Registered office is at T-210 J, Shahpur Jat , New Delhi,Delhi - 110049.